TICKERNERD
Menu
ARMPARMPHealthcare · Biotechnology

ARMP Stock Forecast: Armata Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$5.38
+2.87% on the day

The 2 Wall Street analysts covering Armata Pharmaceuticals, Inc. hold a median 12-month price target of $18 — +225.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 12 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$200.0M
Ticker Nerd rank
71 / 100
Median analyst target
$18
Analysts covering
2
Revenue$0.0
Operating income−$8.8M
Net income−$115.3M
Free cash flow−$5.8M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.5%
1M
+26.6%
YTD
−14.3%
1Y
+81.8%
From 52W high
−63.6%
From 52W low
+86.8%
$3
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARMP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Armata Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
71 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
95
Value
83
Size
68
Momentum
68
Revisions
67
Volatility
61
Quality
49
Growth
28
Issuance
15

Accruals (95): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARMP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARMP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Oct 25Jan 26Apr 26Jul 26ARMPHigh $20Median $18Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $15Median $18High $20

The green dot is the last close — the median target sits +225.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Feb 2026HC Wainwright & Co.MaintainsBuy—
5 Jan 2026Jones TradingInitiatesBuy—
19 May 2025HC Wainwright & Co.MaintainsBuy—
19 Dec 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
12 Nov 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
11 July 2024HC Wainwright & Co.ReiteratesBuy—
8 May 2024HC Wainwright & Co.ReiteratesBuy—
22 Mar 2024HC Wainwright & Co.MaintainsBuy—
14 Aug 2023HC Wainwright & Co.ReiteratesBuy—
12 May 2023HC Wainwright & Co.ReiteratesBuy—
17 Mar 2023HC Wainwright & Co.ReiteratesBuy—
7 Mar 2023HC Wainwright & Co.ReiteratesBuy—
22 Mar 2021HC Wainwright & Co.MaintainsBuy—
15 May 2020H.C. WainwrightReiteratesBuy—
15 May 2020HC Wainwright & Co.ReiteratesBuy—
20 Mar 2020H.C. WainwrightReiteratesBuy—
20 Mar 2020HC Wainwright & Co.ReiteratesBuy—
6 Feb 2020Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARMP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ARMP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Armata Pharmaceuticals, Inc. returned +81.8% against +17.5% for the S&P 500, dividends included.

ARMP vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Oct 25Jan 26Apr 26Jul 26ARMPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ARMP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Armata Pharmaceuticals, Inc. (ARMP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.1×

Cheaper than 83% of US stocks

Price / sales
36.1×

Cheaper than 7% of US stocks

Price / book
−0.6×

Cheaper than 94% of US stocks

EV / EBITDA
−14.7×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
15.7%

Higher than 63% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−410.8%

Higher than 8% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
79.5%

Higher than 95% of US stocks

Return on assets
−25.8%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Armata Pharmaceuticals, Inc. (ARMP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Armata Pharmaceuticals, Inc. has a market value of $200.0M and an enterprise value of $490.0M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0. The latest quarter grew 15.7% year on year.

  • Net income over the same four quarters: −$282.6M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$24.5M, after $506K of capital spending.

  • Shares outstanding: 37.2M.

  • Trailing P/E: −1.1×; forward P/E: −3.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Armata Pharmaceuticals, Inc. employs 61 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

ARMP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARMPArmata Pharmaceuticals, Inc.$200.0M
71
DTILPrecision BioSciences, Inc.$197.9M
68
CHRSCoherus Oncology, Inc.$198.8M
52
KRROKorro Bio, Inc.$199.2M
29
ANTXAN2 Therapeutics, Inc.$194.4M
72
NERVMinerva Neurosciences, Inc.$193.3M
32
ORMPOramed Pharmaceuticals, Inc.$191.1M
82

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Armata Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARMP news & analysis

Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

PRNewsWire · 10 Sept 2026neutral

Armata Pharmaceuticals announced that Deborah Birx, M.D. will participate in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 2026. The company is a late clinical-stage biotech focused on developing bacteriophage therapeutics for antibiotic-resistant bacterial infections.

Why it matters — ARMP watchers would care because conference participation provides an opportunity for company leadership to present its bacteriophage therapeutic pipeline to investors and the wider investment community.

Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

PRNewsWire · 3 Sept 2026positive

Armata Pharmaceuticals announced a publication in the peer-reviewed Journal of Molecular Biology that advances understanding of phage biology to support the development of next-generation antibacterials. The company focuses on developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections.

Why it matters — A peer-reviewed publication strengthening the scientific foundation of Armata's phage-based antibacterial platform is a notable, credibility-building milestone for those tracking the company's development progress.

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

PRNewsWire · 12 Aug 2026neutral

Armata Pharmaceuticals announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company reported that it continues to finalize activities required to initiate a pivotal Phase 3 superiority study of its bacteriophage therapeutic AP-SA02 in complicated Staphylococcus aureus infections.

Why it matters — The update signals that Armata is moving forward with the preparation of a pivotal Phase 3 study of AP-SA02, a key late-stage program for its pathogen-specific bacteriophage therapeutics.

FAQ

Frequently asked questions about ARMP stock

What is the ARMP stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Armata Pharmaceuticals, Inc. have a median 12-month price target of $18, with estimates ranging from $15 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARMP stock a buy right now?

Of the 2 analysts covering Armata Pharmaceuticals, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Armata Pharmaceuticals, Inc. 71 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARMP?

As at 12 Sept 2026, Armata Pharmaceuticals, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (95 of 100).

Will ARMP stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +225.3% from the last close, and Ticker Nerd's factor model ranks Armata Pharmaceuticals, Inc. 71 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARMP stock forecast for 2030?

No analyst covering Armata Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARMP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $20 over the next 12 months.

How has ARMP stock performed over the past year?

Armata Pharmaceuticals, Inc. returned +81.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Armata Pharmaceuticals, Inc. do?

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections.

What is the latest news on ARMP?

The most recent item we track (PRNewsWire, 10 Sept 2026): "Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference". Armata Pharmaceuticals announced that Deborah Birx, M.D. will participate in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 2026. The company is a late clinical-stage biotech focused on developing bacteriophage therapeutics for antibiotic-resistant bacterial infections.

Company

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company’s current work centers on phage-based medicines designed to target specific bacterial pathogens, with programs addressing infections such as Staphylococcus aureus bacteremia and Pseudomonas aeruginosa-related disease. Its platform combines natural and synthetic bacteriophages with proprietary engineering, microbiological surveillance, and drug development capabilities to support product design, manufacturing, and clinical testing. Armata Pharmaceuticals operates as a specialist in infectious disease therapeutics, serving an important role in the broader biopharmaceutical market by advancing alternative approaches to conventional antibiotics.

CEO Dr. Deborah L. Birx M.D. · 61 employees · United States · https://www.armatapharma.com